Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833368 | 0.97 | RORC (0.38) | RORCHDAC8PTPN1ERBB2ERBB4 | |
| SCHEMBL4843106 | 0.92 | RORC (0.43) | RORCERBB2ERBB4 | |
| SCHEMBL4845401 | 0.90 | RORC (0.43) | RORCERBB2ERBB4 | |
| SCHEMBL4844796 | 0.90 | PTPN1 (0.39) | RORCHDAC8PTPN1 | |
| SCHEMBL4842798 | 0.89 | PTPN1 (0.39) | RORCHDAC8PTPN1 | |
| SCHEMBL4833738 | 0.87 | PTPN1 (0.39) | RORCPTPN1 | |
| SCHEMBL4841421 | 0.87 | RORC (0.40) | RORCADAMTS4MMP13ADAMTS5 | |
| SCHEMBL4841876 | 0.86 | RORC (0.39) | RORCADAMTS4MMP13ADAMTS5 | |
| SCHEMBL4843243 | 0.86 | RORC (0.42) | RORCADAMTS4MMP13ADAMTS5 | |
| SCHEMBL4891032 | 0.85 | POLB (0.40) | RORCADAMTS4MMP13ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | RORC 1777/4885HDAC8 1142/4885PTPN1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.